News
CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...
1d
MedPage Today on MSNGabapentin vs Pregabalin Study Teases Out Heart Risks
Pregabalin was associated with an increased risk for heart failure relative to another widely used gabapentinoid, based on an ...
Kisunla’s active substance is donanemab, a monoclonal antibody that targets and clears amyloid-beta plaques in the brain, a ...
The European drug authority recommends refusal of marketing authorization due to evidence gaps in quality and efficacy.
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Medicines Agency (EMA) has ...
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the Stocks With Huge Catalysts on the Horizon. On July 25, Ionis ...
2d
Pharmaceutical Technology on MSNBeOne Medicines’ BTK degrader gains EMA PRIME designation
The designation was based on the therapy’s novel mechanism and data showing its anti-tumour activity in B-cell malignancies.
5don MSN
KalVista Pharmaceuticals (KALV) Received Positive Opinion From the European Medicines Agency
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) is one of the Stocks With Huge Catalysts on the Horizon. On July 25, KalVista ...
LONDON -- The European Medicines Agency has recommended authorizing a twice-yearly injectable drug aimed at preventing HIV, which scientists say could help end the virus' transmission.
Eli Lilly said on Friday that the European Medicines Agency (EMA) has recommended approval of its drug Kisunla for certain ...
The European Union's drugs regulator has recommended approval of Gilead Sciences' lenacapavir, a twice-yearly injection, for ...
"Tevimbra is already approved in the EU across multiple settings in [non-small cell lung cancer], the most common form of lung cancer, and this positive CHMP opinion expands its potential to help ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results